title: Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.
abstract: Beta adrenergic receptor blocking drugs (β-blockers) are used chronically in many cardiovascular diseases such as hypertension, ischemic heart disease, arrhythmia, and heart failure. Beneficial effects are associated with the inhibition of symphathetic nervous system hyperactivity, reduction of heart rate, and remodeling by blocking the mitogenic activity of catecholamines. A possible effect of β-blockers on substrate metabolism has also been suggested. The direct effects of β-blockers on mouse C2C12 cells were investigated in this study. C2C12 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and differentiated into myotubes in the same medium that contained 1% FBS. Palmitic acid oxidation and glycolysis were measured by using [9,10-(3)H]palmitate and [5-(3)H]glucose, respectively. The amount of (3)H(2)O was measured as an indicator of substrate usage. Carvedilol (100 µmol/L) inhibited palmitate oxidation and increased glycolysis by nearly 50%. Prazosin altered substrate metabolism in a similar fashion as carvedilol, whereas propranolol or bisoprolol were devoid of metabolic effects. When added to mimic sympathetic activation, epinephrine stimulated glycolysis but did not alter fatty acid oxidation. Based on these results, carvedilol appears to have direct effects on substrate metabolism that are related to the blockade of α1 adrenergic receptors.
authors.affiliation: Department of Pharmacology, Faculty of Pharmacy, Ankara University, Tandogan, Turkey. abesikci@ankara.edu.tr
authors.forename: Arzu
authors.initials: A
authors.lastname: Onay-Besikci
authors.forename: Elif
authors.initials: E
authors.lastname: Suzmecelik
authors.forename: A Tanju
authors.initials: AT
authors.lastname: Ozcelikay
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D017298:Bisoprolol / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology*; D000077261:Carvedilol; D002460:Cell Line; D004837:Epinephrine / Q000494:pharmacology; D005227:Fatty Acids / Q000378:metabolism*; D006019:Glycolysis / Q000187:drug effects*; D051379:Mice; D010084:Oxidation-Reduction; D019308:Palmitic Acid / Q000378:metabolism; D011224:Prazosin / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D005227:Fatty Acids; D011412:Propanolamines; D013566:Sympathomimetics; D000077261:Carvedilol; D019308:Palmitic Acid; D011433:Propranolol; D011224:Prazosin; D017298:Bisoprolol; D004837:Epinephrine